why choose us

Clinical Trials Search

Showing 8,310 of 132,366 result(s)
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Status: ACTIVE_NOT_RECRUITING

Condition: Overweight

Interventions: Administered SC.

Date: 2023-09-11

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Status: Completed

Condition: Obesity

Interventions: NNC0487-0111 will be administered as a subcutaneous (s.c.
under the skin) injection.

Date: 2023-09-11

Sonodynamic Therapy in Patients With Recurrent GBM

Status: Completed

Condition: Recurrent Glioblastoma

Interventions: 5-ALA (20mg;kg orally) given ~6 hours prior to LIFU.
Focused ultrasound will target a maximum of 50% of the tumor.

Date: 2023-09-10

Effect of Vagal Nerve Stimulation on Gastric Motor Functions

Status: NOT_YET_RECRUITING

Condition: Epilepsy

Interventions: Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses.
The implanted electrodes transmit electric

Date: 2023-09-10

PainChek® US Validation Nursing Home Study

Status: Completed

Condition: Dementia

Interventions: Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profes

Date: 2023-09-10

Mother-Baby Study - Observational

Status: Completed

Condition: Obesity, Childhood

Interventions: Mother participates in bonding activity with infant at ages 1, 3, and 6 months

Date: 2023-09-10

The Role of Amnion Membrane Allografts in Nipple Preservation

Status: NOT_YET_RECRUITING

Condition: Mastectomy

Interventions: Dehydrated human amnion;chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management

Date: 2023-09-09

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

Status: Completed

Condition: Moderate Plaque Psoriasis

Interventions: Guselkumab will be administered as subcutaneous injection.

Date: 2023-09-09

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Status: Completed

Condition: Post-transplant Lymphoproliferative Disorder

Interventions: Given at 1.8 mg;kg

Date: 2023-09-09